Ibio vs Serina Therapeutics
Serina Therapeutics is the larger business, with $130,000 of revenue in fiscal 2025 against $100,000 for Ibio (1.3 times as much). Serina Therapeutics grew faster (132.1% against -75.0%). Serina Therapeutics kept more of each dollar of sales as profit: a net margin of -14755.4% against -33044.0%.
| Latest fiscal year | IbioIBIO, 2026 | Serina TherapeuticsSER, 2025 |
|---|---|---|
| Revenue | $100,000 | $130,000 |
| Revenue growth | -75.0% | 132.1% |
| Net income | −$33.0m | −$19.2m |
| Operating margin | -35141.0% | -18478.5% |
| Net margin | -33044.0% | -14755.4% |
| Return on equity | -65.7% | — |
| Free cash flow | −$23.8m | −$18.0m |
| Cash | $56.4m | $3.1m |
| Total debt | $0 | $2.9m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | 16 |
| Market value | $45.5m | $46.7m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 32 (Weak) |
| Insider trades, 12 months | 4 buys, 0 sales | 7 buys, 25 sales |